Turkovac
This is an old revision of this page, as edited by Citation bot (talk | contribs) at 01:17, 2 November 2022 (Alter: template type. Add: date, newspaper. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by Anas1712 | #UCB_toolbar). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | ERUCOV-VAC |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg){kind=small} COVID-19 portal |
Turkovac[1] (pronunciation: [[Help:IPA/Turkish|['tɜ:rkəvæk]]]) (temporarily named as ERUCOV-VAC[2]) is a COVID-19 vaccine developed by Health Institutes of Türkiye and Erciyes University.
Clinical trials
In November 2020, TURKOVAC started on phase I trials with 44 participants in Turkey.[3]
In February 2021, TURKOVAC started on phase II trials with 250 participants in Turkey.[4]
In June 2021, TURKOVAC started on phase III trials with 40,800 participants in Turkey.[5]
Authorization
On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.[6] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.[7]
References
- ^ Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
- ^ "Domestic COVID-19 jab Turkovac begins Phase 3 trials in Turkey". Daily Sabah. 22 June 2021. Retrieved 23 June 2021.
- ^ Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)" at ClinicalTrials.gov
- ^ Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 " at ClinicalTrials.gov
- ^ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
- ^ "Turkey issues emergency-use authorization for its domestically produced vaccine". The New York Times. 22 December 2021. Retrieved 28 December 2021.
- ^ "Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
- Articles with short description
- Short description is different from Wikidata
- Use dmy dates from April 2021
- Drugs with non-standard legal status
- Infobox drug articles with non-default infobox title
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- Pages with plain IPA
- All stub articles